ArticleBMC pediatrics2025
Long-term risk of allergic disorders following Kawasaki disease: a population-based cohort study.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From acute immune storm to lifelong vascular risk: a paradigm shift in Kawasaki disease as a chronic disease model.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKawasaki disease (KD) is an acute systemic vasculitis primarily affecting children under five years old. While its etiology remains unclear, immune dysregulation has been implicated, suggesting a potential link between KD and allergic diseases. Previous epidemiological studies have reported inconsistent findings regarding this association across different countries. This study aims to investigate the association between KD and allergic diseases in Korea.
methodsA nationwide population-based cohort study was conducted utilizing data from the Korean National Health Insurance database. KD cases were defined as admissions with a primary diagnosis of KD plus treatment records for immunoglobulin or aspirin. The control group had no KD diagnosis. Between 2008 and 2015, 41,806 KD cases were matched 1:4 with 163,548 controls using propensity score matching. The incidence and prevalence of asthma, rhinitis, atopic dermatitis, and urticaria from 2017 to 2021 were analyzed using hazard ratios (HRs) and odds ratios (ORs).
resultsMean age was 2.63 ± 1.84 years for KD patients and 2.64 ± 1.85 years for controls (P = 0.119). The proportion of females was 42.20% in the KD group and 42.60% in the control group (P = 0.145). KD patients showed significantly higher risks for developing rhinitis (HR 1.045, 95%CI 1.013-1.078) and urticaria (HR 1.139, 95%CI 1.085-1.197). However, no significant association was found in the incidence of asthma or atopic dermatitis. KD diagnosis at age 5 or older was associated with decreased risk of all allergic disorders. The prevalence of all allergic disorders studied was significantly higher in the KD group, with the strongest associations observed for rhinitis (OR 1.178, 95%CI 1.151-1.205) and urticaria (OR 1.192, 95%CI 1.155-1.230). Gender and urban living also influenced the prevalence of allergic disorders. A sensitivity analysis conducted to account for the COVID-19 pandemic showed consistent results, confirming the association between KD and increased risk and prevalence of allergic disorders.
conclusionsThis study demonstrates a significant association between Kawasaki disease and increased risk of allergic disorders, particularly rhinitis and urticaria. These findings suggest potential shared pathogenesis between the two conditions and highlight the need for long-term monitoring of allergic conditions in KD patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.